Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;23(3):277-286.
doi: 10.1007/s40257-022-00675-2. Epub 2022 Mar 5.

Cutaneous Manifestations of SARS-CoV-2 Infection

Affiliations
Review

Cutaneous Manifestations of SARS-CoV-2 Infection

Thy Huynh et al. Am J Clin Dermatol. 2022 May.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the coronavirus disease 2019 (COVID-19) pandemic, affecting people worldwide. SARS-CoV-2 infection is a multisystem disease with potential for detrimental effects on various systemic organs. It affects people of all ages with varying degrees of disease severity. Patients with SARS-CoV-2 infection commonly present with dry cough, fever, and fatigue. A clinical spectrum of skin findings secondary to SARS-CoV-2 has also been reported. The most common cutaneous patterns associated with COVID-19 are chilblain-like lesions (CBLL), maculopapular lesions, urticarial lesions, vesicular lesions, and livedoid lesions. Other skin findings secondary to SARS-COV-2 infection are erythema multiforme (EM)-like lesions and skin findings associated with multisystem inflammatory syndrome in children (MIS-C) and rarely multisystem inflammatory syndrome in adults (MIS-A). Physician awareness of skin manifestations of SARS-CoV-2 infection can help with early identification and treatment. This narrative review provides an update of various skin manifestations reported with SARS-CoV-2 infection, including clinical presentation, proposed pathogenesis, histopathology, prognosis, and treatment options.

PubMed Disclaimer

Conflict of interest statement

Dr Huang serves on the Scientific Advisory Board for EllaOla. The remaining authors have no conflicts of interest.

Figures

Fig. 1
Fig. 1
a Dusky erythematous and edematous plaques involving the left second, third, and fourth toes. b Dusky erythematous and edematous plaques on the left toes
Fig. 2
Fig. 2
Pink pruritic edematous wheals on trunk and arms
Fig. 3
Fig. 3
Target-like papule on the index finger

Similar articles

Cited by

References

    1. Drenovska K, Schmidt E, Vassileva S. Covid-19 pandemic and the skin. Int J Dermatol. 2020;59(11):1312–1319. doi: 10.1111/ijd.15189. - DOI - PMC - PubMed
    1. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212–e213. doi: 10.1111/jdv.16387. - DOI - PubMed
    1. Carrascosa JM, Morillas V, Bielsa I, Munera-Campos M. Cutaneous manifestations in the context of SARS-CoV-2 infection (COVID-19) Actas Dermosifiliogr. 2020;111(9):734–742. doi: 10.1016/j.ad.2020.08.002. - DOI - PMC - PubMed
    1. Visconti A, Bataille V, Rossi N, et al. Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection. Br J Dermatol. 2021;184(5):880–887. doi: 10.1111/bjd.19807. - DOI - PMC - PubMed
    1. Gisondi P, Di Leo S, Bellinato F, Cazzaniga S, Piaserico S, Naldi L. Time of onset of selected skin lesions associated with COVID-19: a systematic review. Dermatol Ther (Heidelb). 2021;11(3):695–705. doi: 10.1007/s13555-021-00526-8. - DOI - PMC - PubMed

Supplementary concepts